Aimi Vaccine mRNA shingles vaccine approved for clinical trials
May 20, 2025
Source: drugdu
85
On May 19, Aimi Vaccine (06660) announced that its mRNA shingles vaccine has recently obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, which corresponds to the approval of the U.S. Food and Drug Administration for clinical trials in March 2025. This dual approval fully verifies the strength of the company's mRNA technology platform.
In preclinical trials, results from third-party testing units showed that the vaccine developed by the company was significantly higher than the internationally marketed recombinant subunit control vaccine in terms of specific T cell immunity, specific IgG antibody titer and membrane antigen fluorescent antibody (FAMA) titer.
Currently, no mRNA shingles vaccine has been approved for marketing internationally, and the market potential is huge. It is estimated that by 2030, the Chinese market size will reach about 20 billion yuan, and the global market size will reach about 23.9 billion US dollars. The launch of this product is expected to bring considerable performance growth to the company and reshape the market landscape.
https://finance.eastmoney.com/a/202505193407950828.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted July 10, 2025
- Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development July 10, 2025
- Small nucleic acid therapy challenges GLP-1 giants July 10, 2025
- Baili Tianheng BL-B01D1 Update Progress July 10, 2025
- FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema July 10, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
